leisure time -WSS

leisure time

author：hotspot 2025-09-29 16:46:03 - browse：66

Liver illustration — Hyacinth Empinado/STAT

SAN DIEGO — The American Diabetes Association said Sunday that all adults with type 2 diabetes or prediabetes should be screened for nonalcoholic fatty liver disease, an increasingly prevalent condition that can lead to serious liver damage.

There are no approved medications for the disease, but among available diabetes drugs, the ADA singled out GLP-1 treatments as an option doctors could consider, according to recommendations published during the annual ADA conference.

GLP-1 treatments, such as Ozempic and Mounjaro, are a class of drugs that have grown widely popular for their efficacy not only in lowering blood sugar, but also cutting weight. Drugmakers have started to study them in liver disease, and while some trials have shown they may offer some benefits, they haven’t yet been shown to improve harmful liver scarring.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： With FDA staff opposed to Sarepta therapy, top official intervened

WSS

Colonoscopy prep: Liquid

The strategy behind pharma's lawsuits over drug pricing reform

Do masks work? RCTs can't tell us

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Why we need to separate burnout from moral injury in health care

Positive childhood experiences can help future health

leisure time

leisure time

entertainment

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Anesthesiologist group: stop taking Ozempic before surgery

Virtual Event: March of the Biosimilars

Virginia high school admissions case could be legal follow

In areas with more Black doctors, Black people live longer

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Gene editing the human germline: What are the risks?

Walensky prepares to leave CDC — and Congress — behind

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

focus

Nurses recount patients attacks

SCOTUS questions limit to govt efforts to fight misinformation

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Death of patient in Alzheimer’s trial raises question of possible risks

Health AI adoption puts security, privacy startups on investors' radar

Future doctors should be trained to promote social change

explore

leisure time

hotspot

hotspot